Parents Push One Rare-Disease Drug Through FDA, Not Its Successor

Bookmark
(Bloomberg Opinion) -- For a small biotechnology firm, Sarepta Therapeutics Inc. has made a lot of waves at the Food and Drug Administration. The 2016 approval of its first drug, Exondys 51 – which...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.